Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 18/20 | 0.70 |
| ▸ | AGXT | P21549 | 5/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2514135 | 0.98 | IDO1 (0.71) | IDO1AGXTCYP3A4TP53TSHR | |
| SCHEMBL9767549 | 0.83 | IDO1 (1.00) | IDO1AGXTCYP3A4 | |
| Hydrochloric Acid SCHEMBL1715908 | 0.81 | IDO1 (1.00) | IDO1AGXTCYP3A4 | |
| Hydrochloric Acid SCHEMBL1715890 | 0.81 | IDO1 (1.00) | IDO1AGXTCYP3A4 | |
| SCHEMBL12873450 | 0.80 | IDO1 (0.45) | IDO1CYP3A4TP53TSHR | |
| SCHEMBL1520857 | 0.79 | IDO1 (0.54) | IDO1AGXTCYP3A4TP53 | |
| SCHEMBL1145754 | 0.78 | IDO1 (0.44) | IDO1CYP3A4TP53TSHR | |
| SCHEMBL1145751 | 0.78 | IDO1 (0.44) | IDO1CYP3A4TP53TSHR | |
| SCHEMBL1520724 | 0.76 | IDO1 (0.56) | IDO1AGXTCYP3A4 | |
| SCHEMBL11007814 | 0.76 | IDO1 (0.66) | IDO1AGXTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115362161-B | Process for preparing 3' -O-amino-2 ' -deoxyribonucleoside-5 ' -triphosphate | DNA斯克瑞普特公司 | 2025-03-07 | — | — | CN | claimed |
| US-11661436-B2 | Method for preparing 3′-o-amino-2′-deoxyribonucleoside-5′-triphosphates | DNA SCRIPT SAS (FR) | 2023-05-30 | — | — | US | claimed |
| EP-4126895-A1 | METHOD FOR PREPARING 3'-O-AMINO-2'-DEOXYRIBONUCLEOSIDE-5'-TRIPHOSPHATES | DNA Script (FR) | 2023-02-08 | — | — | EP | claimed |
| CN-115362161-A | Process for preparing 3' -O-amino-2 ' -deoxyribonucleoside-5 ' -triphosphates | DNA斯克瑞普特公司 | 2022-11-18 | — | — | CN | claimed |
| US-20210300961-A1 | METHOD FOR PREPARING 3'-O-AMINO-2'-DEOXYRIBONUCLEOSIDE-5'-TRIPHOSPHATES | DNA SCRIPT SAS (FR) | 2021-09-30 | — | — | US | claimed |
| CN-115362161-B | Process for preparing 3' -O-amino-2 ' -deoxyribonucleoside-5 ' -triphosphate | DNA斯克瑞普特公司 | 2025-03-07 | — | — | CN | disclosed |
| US-11661436-B2 | Method for preparing 3′-o-amino-2′-deoxyribonucleoside-5′-triphosphates | DNA SCRIPT SAS (FR) | 2023-05-30 | — | — | US | disclosed |
| EP-4126895-A1 | METHOD FOR PREPARING 3'-O-AMINO-2'-DEOXYRIBONUCLEOSIDE-5'-TRIPHOSPHATES | DNA Script (FR) | 2023-02-08 | — | — | EP | disclosed |
| CN-115362161-A | Process for preparing 3' -O-amino-2 ' -deoxyribonucleoside-5 ' -triphosphates | DNA斯克瑞普特公司 | 2022-11-18 | — | — | CN | disclosed |
| WO-2021198040-A1 | METHOD FOR PREPARING 3'-O-AMINO-2'-DEOXYRIBONUCLEOSIDE-5'-TRIPHOSPHATES. | DNA SCRIPT (FR) | 2021-10-07 | — | — | WO | disclosed |
| US-20210300961-A1 | METHOD FOR PREPARING 3'-O-AMINO-2'-DEOXYRIBONUCLEOSIDE-5'-TRIPHOSPHATES | DNA SCRIPT SAS (FR) | 2021-09-30 | — | — | US | disclosed |
| US-8247413-B2 | e.g. N-[2-(3-fluorophenyl)ethyl]-N'-isoquinolin-5-ylurea; opioid receptor inhibitor; analgesic, antiinflammatory agent; inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity | ABBOTT LABORATORIES (US) | 2012-08-21 | — | — | US | disclosed |
| US-20080214524-A1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2008-09-04 | — | — | US | disclosed |
| US-7335678-B2 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1(VR1) receptor | ABBOTT LABORATORIES (US) | 2008-02-26 | — | — | US | disclosed |
| US-6933311-B2 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2005-08-23 | — | — | US | disclosed |
| US-20050113576-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES | 2005-05-26 | — | — | US | disclosed |
| US-20040209884-A1 | Fused azabicycic compounds that inhibit vanilloid receptor subtype 1(VR1) receptor | ABBVIE INC. | 2004-10-21 | — | — | US | disclosed |
| US-20040157849-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2004-08-12 | — | — | US | disclosed |
| US-20030158198-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2003-08-21 | — | — | US | disclosed |
| US-4293715-A | FUNGICIDES, BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1981-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214524-A1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | TRPV1, TMEM109, VIPR1 | IDO1 1470/4885AGXT 4213/4885CYP3A4 1234/4885 |
| US-20210300961-A1 | METHOD FOR PREPARING 3'-O-AMINO-2'-DEOXYRIBONUCLEOSIDE-5'-TRIPHOSPHATES | DUT, RNMT, NUDT1 | IDO1 997/4885AGXT 971/4885CYP3A4 825/4885 |
| US-20030158198-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, VIPR1, TMEM109 | IDO1 1232/4885AGXT 4158/4885CYP3A4 1208/4885 |
| US-20040157849-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, VIPR1, TMEM109 | IDO1 1192/4885AGXT 4234/4885CYP3A4 1191/4885 |
| US-11661436-B2 | Method for preparing 3′-o-amino-2′-deoxyribonucleoside-5′-triphosphates | DUT, RNMT, NUDT1 | IDO1 984/4885AGXT 924/4885CYP3A4 879/4885 |
| US-20040209884-A1 | Fused azabicycic compounds that inhibit vanilloid receptor subtype 1(VR1) receptor | TRPV1, TMEM109, GPR55 | IDO1 859/4885AGXT 4192/4885CYP3A4 1162/4885 |
| US-20050113576-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, TMEM109, VIPR1 | IDO1 1470/4885AGXT 4213/4885CYP3A4 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.